Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.
Fischer L, Steinhilber D, Werz O. Fischer L, et al. Br J Pharmacol. 2004 Jul;142(5):861-8. doi: 10.1038/sj.bjp.0705860. Epub 2004 Jun 14. Br J Pharmacol. 2004. PMID: 15197110 Free PMC article.
In this study, we present the molecular pharmacological profile of the novel nonredox-type 5-LO inhibitor CJ-13,610 that was evaluated in various in vitro assays. ...In summary, CJ-13,610 m …
In this study, we present the molecular pharmacological profile of the novel nonredox-type 5-LO …
Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor.
Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, López-Parra M, Masferrer JL, Arroyo V, Clària J. Horrillo R, et al. J Pharmacol Exp Ther. 2007 Dec;323(3):778-86. doi: 10.1124/jpet.107.128264. Epub 2007 Aug 31. J Pharmacol Exp Ther. 2007. PMID: 17766677
Additional pharmacological profiling of SC-236 and CJ-13,610 was performed in macrophages, the primary hepatic inflammatory cell type. In these cells, SC-236 inhibited prostaglandin (PG) E2 formation in a concentration-dependent manner, w …
Additional pharmacological profiling of SC-236 and CJ-13,610 was performed in macrophages, the primary he …
Feedback